Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

27.02 +0.80 (+3.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Celldex Therapeutics

< Previous 1 2 3 4 Next >
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
Via Benzinga
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
Via Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
Via Benzinga
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
Unveiling 4 Analyst Insights On Celldex Therapeutics
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Celldex Therapeutics: Q4 Earnings Insights
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
Via Benzinga
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
Via Benzinga
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. 
Via Investor's Business Daily
Top Picks 2024: Celldex Therapeutics, Inc.
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to... 
Via Talk Markets
Top 4 Health Care Stocks That May Crash This Month
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. 
Via InvestorPlace
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share. 
Via Benzinga
Why Celldex Therapeutics Blasted 13% Higher on Monday
The biotech's CSU treatment advanced in the laboratory. 
Via The Motley Fool
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to... 
Via Benzinga
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.